REFERENCES
1. Leach DR, Krummel MF, Allison JP. Enhancement of antitumor immunity by CTLA-4 blockade. Science 1996;271:1734-6.
3. Cong L, Ran FA, Cox D, Lin S, Barretto R, Habbib N, Hsu PD, Wu X, Jiang W, Marraffini LA, Zhang F. Multiplex genome engineering using CRISPER/Cas systems. Science 2013;339:819-23.
4. Currie GA. Eighty years of immunotherapy: a review of immunological methods used for treatment of human cancer. Brit J Cancer 2012;26:141-53.
5. Markus MY, Sykes M. Tolerance and cancer: mechanisms of tumor envision and strategies for breaking tolerance. J Clin Oncol 2004;22:1136-51.
7. Chin LT, Chu C, Chen HM, Wang DW, Liao SK. Immune intervention with monoclonal antibodies targeting to CD152 (CTLA-4) for autoimmune and malignant diseases. Chang Gung Med J 2008;31:1-15.
9. Chen DS, Mellman I. Element of cancer immunity and cancer-immune set point. Nature 2017;541:321-30.
10. Chen M, Chen Y, Xiao W, Sun R, Tian Z. NK cell-based immunotherapy for malignant diseases. Cell Mol Immunol 2013;10:230-52.
11. Rosenberg SA, Lotz MT, Muul LM, Leitman S, Chang AE, Ettinghansen SE, Matory YL, Skibber JM, Shilone E, Vetto JT, Sepp CA. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukine-2 to patients with metastatic cancer. N Eng J Med 1985;313:1485-92.
12. West WH, Tauer KW, Yanelli JR, Marshall GD, Orr DW, Thurman GB, Oldham RK. Constant-infusion recombinant interleukine-2 in adoptive immunotherapy of advanced cancer. N Eng J Med 1987;316:898-905.
13. Schmidt-Wolf IG, Negrin RS, Kiem HP, Blume KG, Weissman IL. Use of a SCID mouse/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity. J Exp Med 1991;174:139-49.
14. Rosenberg SA, Packard BS, Aebersold PM, Solomon D, Topalian SL, Toy ST, Simon P, Lotze MT, Yang JC, Seipp CA, Simpson C, Carter C, Bock S, Schwartzentruber D, Wei JP, White DE. Use of tumor-infiltrating lymphocytes and interleukin 2 in the immunotherapy of patients with metastatic melanoma. N Eng J Med 1988;319:1676-80.
15. Albert ML, Sauter B, Bhardwaj N. Dendritic cells acquire antigen from apoptotic cells and induce class I restricted CTLs. Nature 1998;392:86-9.
16. Tarte K, Klein B. Dendritic cell-based vaccine: a promising approach for cancer immunotherapy. Leukemia 1999;13:653-63.
17. Fisher JP, Heuijerjans J, Yan M, Gustafsson K, Anderson J. γδT cells for cancer immunotherapy: a systemic review of clinical trials. Oncoimmunology 2014;3:e27572.
18. Imai C, Iwamoto S, Campana D. Gnetic modification of primary natural killer cells overcome inhibitory signals and induces specific killing leukemic cells. Blood 2005;106:376-83.
19. Chacon JA, Pilon-Thomas S, Sarnail AA, Radvanyi LG. Contiuous 4-1BB co-stimulatoru signals for the optimal expansion of tumor-infiltrating lymphocytes for adoptive T-cell therapy. Oncoimmunology 2013;2:e25581.
20. Rosenberg SA, Restifo NP. Adoptive cell transfer as personalized immunotherapy. Science 2015;348:62-8.
21. Chmielewski M, Hombach AA, Abken A. Antigen-specific T cell activation independent of MHC: chimeric antigen receptor redirected T cells. Front Immunol 2013;4:371.
22. Ferrone S, Marincola FM. Loss of HLA class I antigens by melanomas: molecular mechanisms, functional significanc and clinical relevance. Immunol Today 1995;16:487-94.
23. Garcia-Lora A, Agarra L, Garrdo F. MHC class I antigens, immune surveillance, and tumor immune escape. J Cell Physiol 2003;196:345-55.
24. Muller T, Uherek C, Maki G, Chow KU, Schimpf A, Klingemann HG, Tonn T, Wels WS. Expression of a CD20-specific chimeric antigen receptor enhances cytotoxic activity of NK cells and overcome NK-resistance of lymphoma and leukemia cells. Cancer Immunol Immunother 2008;57:411-23.
25. Cho FN, Chang TH, Shu CW, Ko MC, Liao SK, Wu KS, Yu MS, Lin SJ, Hong YC, Hung CH, Chang YH. Enhanced cytotoxicity of natural killer cells following the acquisition of chimeric antigen receptors through trogocytosis. PLoS One 2014;9:e109352.
26. Hsieh CH, Hsu YJ, Chang CC, Liu HC, Chuang KL, Chuanh CK, Pang ST, Hasumi K, Ferrone S, Liao SK. Total HLA class I loss in a sarcomatoid renal cell carcinoma cell line caused by the coexistence of distinct mutations in the two encoding beta 2 microglobulin genes. Cancer Imminol Immunother 2009;58:395-408.
27. Kolher G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975;256:495-7.
28. Chen HC, Joalland N, Bridgeman JS, Alchami FS, Jarry U, Khan MWA, Piggott L, Shnneik Y, Li J, Herold MJ, Herrmann T, Price DA, Gallimore AM, Clarkson RW, Scotet E, Moser B, Eberl M. Synergistic targeting of breast cancer stem-like cells by human γδ T cells and CD8+ T cells. Immunol Cell Biol 2017;95:620-9.
29. Vesely MD, Kershaw WH, Shreiber RD, Smyth MJ. Natural innate and adaptive immunity to cancer. Annu Rev Immunol 2001;29:235-71.
30. Oldham RK, Liao SK, Ogden JR, Habbard WH. Individually specified drug immunoconjugatein cancer treatment. In: Ceriani RL, editor. Breast Cancer Immunodiagnosis and Immunotherapy. New York: Springer Science/Business Media; 1989. pp. 219-30.
31. Muller A, Homey B, Soto H, Ge N, Cartron D, Buchanan ME, McClanahan T, Murphy E, Yuan W, Wagner SN, Barrera JL, Mohar A, Verastegui E, Zlotnik A. Involvement of chemokine receptors in breast cancer metastasis. Nature 2001;410:50-6.
32. Herman PC, Huber SL, Herrler T, Aicher A, Ellwart JW, Guba M, Bruns CJ, Heeschen C. Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell 2007;1:313-23.
33. Chen HC, Chou ASB, Liu YC, Hseih CH, Kang CC, Pang ST, Yeh CT, Liu HP, Liao SK. Induction of metastatic cancer stem cells from the NK/LAK-resistant floating, but not adherent, subset of the UP-LN1 carcinoma cell line by IFN-γ. Lab Invest 2010;91:1502-13.
34. Ting LL, Chou ASB, Hsieh CH, Hsiung SC, Pang ST, Liao SK. Withaferin-A targeting both cancer stem cells and metastatic cancer stem cells in the UP-LN1 carcinoma cell model. J Cancer Metastasis Treat 2016;2:29-40.
35. Hsieh CH, Hsiung SC, Wu-Chou YH, Pang ST, Chuang CK, Liao SK. Differential expression of CD44 and CD24 markers discriminates the epithelioid from the fibroblastoid subset in a sarcomatoid renal cell carcinoma cell line: suggestive evidence of the existence of cancer stem cells in both subsets with sorted cells. Oncotarget 2016;8:15593-609.
36. Ahmed N, Salsman VS, Kew Y, Shaffer D, Powell S, Zhang YJ, Grossman PG, Heslop H, Gottschalk S. HER2-specific T cells target primary glioblasoma stem cells and induce regression of autologous experimental tumors. Clin Cancer Res 2010;16:474-85.
37. Mao G, Sampath P, Sengupter S. Updates on chimeric antigen receptor-mediated glioblastoma immunotherapy. Rhode Island Med J 2017;100:39-42.
38. Grossenbacker SK, Canter RJ, Murphy WJ. Natural killer cell immunotherapy to target stem-like tumor cells. J Immuno Ther Cancer 2016;4:19.
39. Wei F, Rong XX, Xie RY, Jia LT, Wang HY, Qin YJ, Chen L, Shen HF, Lin XL, Yang J, Yang S, Hao WC, Chen Y, Xiao SJ, Zhou HR, Lin TY, Chen YS, Sun Y, Yao KT, Xiao D. Cytokine-induced killer cells efficiently kill stem-like cancer cells of nasopharyngeal carcinoma via the NKG2D-ligands recognition. Oncotarget 2015;6:35023-39.
40. Lee TC, Choi BY. Withaferin-A - a natural anticancer agent with pleiotropic mechanisms of action. Int J Mol Sci 2016;17:290.
41. Sounni NE, Noel A. Targeting the tumor microenvironment for cancer therapy. Clin Chem 2013;59:85-93.
42. Stambrook PJ, Maher J, Farzaneh F. Cancer immunotherapy: whence and whither. Mol Cancer Res 2017;15:635-50.
43. Iwai Y, Hamanish J, Chamato K, Honjo T. Cancer immunotherpies targeting the PD1 signaling pathway. J Biomed Sci 2017;24:26.
45. Ott PA, Hu Z, Keskin D, Shukla SA, Sun H, Buzym DJ, Zhang W, Luoma A, Giobbie-Hurder A, Petre L, Chen C, Olieve O, Carter TA, Li S, Lieb DJ, Eisenhaure T, Gjini E, Stevens J, Lane WJ, Javeri I, Nellalappan K, Salazar AM, Daley H, Seaman M, Buchbinder EI, Yoon CH, Harden M, Lennon N, Garbriel S, Rodig SJ, Barden M, Aster JC, Getz G, Wucherpfennig K, Neubergt D, Ritz J, Lander ES, Frisch EF, Hacohen N, Wu JC. An immunogenic personal neoantigen vaccine for patients with melanoma. Nature 2017;542:217-21.
46. Sahin U, Derhovanessian E, Miller M, Kloke BP, Simin P, Lower M, Bukuri V, Tadmor AD, Luxemburger U, Barbara Schrörs B, Omokoko T, Vormehr M, Albrecht C, Paruzynski A, Andreas N, Kuhn AN, Buck J, Heesch S, Schreeb KH, Muiller F, Ortseifer I, Vogler I, Godehardt E, Attig S, Rae R, Breitkreuz A, Tolliver C, Suchan M, Martic G, Hohberger A, Sorn P, Dickmann J, Ciesla J, Waksmann O, Bruck AK, Witt M, Zillgen M, Rothermel A, Kaesmann B, Langer D, Bolte S, Diken M, Kreiter S, Langer D, Bolte S, Diken M, Kreiter S, Nemecek R, Gebhardt C, Grabbe S, Holler C, Utikal J, Huber C, Loquai C, Tureci O. Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer. Nature 2017;547:222-6.
48. Oldham RK. The cure for cancer. J Biol Resp Modif 1985;3:111-6.
49. Scarfo I, Maus MV. Current approaches to increase CAR T cell potency in solid tumors: targeting the tumor microenvironment. J Immuno Ther Cancer 2017;5:28.
51. Novartis announces first CAR-T cell therapy BLA for pediatric and young adult patients with r/r B-cell ALL granted FDA Priority Review. Available from: https://www.novartis.com/news/media-releases/novartis-announces-first-car-t-cell-therapy-blapediatric-and-young-adult. [Last accessed on 15 Jan 2018].
52. Roots Analysis. T-Cell Immunotherapy Market (2nd Edition), 2017-2030. Available from: https://www.rootsanalysis.com/reports/view_document/t-cell-immunotherapy-market-2nd-edition-2017-2030/151.html. [Last accessed on 15 Jan 2018].
